여행용 백신 시장 : 백신 유형, 제형, 연령층, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Travel Vaccines Market is projected to grow by USD 10.53 billion at a CAGR of 9.29% by 2032.

Travel vaccines are a critical preventive-health category for travel clinics, hospitals, occupational health providers, and pharmacy-based immunization programs. Demand is shaped by the recovery of international mobility, destination-specific disease exposure, changing entry requirements, and improved consumer awareness of vaccine-preventable diseases such as yellow fever, typhoid, hepatitis A, hepatitis B, Japanese encephalitis, rabies, meningococcal disease, cholera, and seasonal influenza.

For care delivery organizations, the strongest opportunity is no longer limited to administering vaccines before departure. High-performing providers are building end-to-end travel medicine services that combine itinerary-based risk assessment, vaccine history review, digital reminders, documentation support, adverse event monitoring, and post-travel care pathways. This integrated model improves patient adherence and creates a defensible position in a market where convenience, clinical accuracy, cold-chain reliability, and verified guidance from recognized public health authorities are essential.

Transformative Shifts in the Travel Vaccines Landscape

The travel vaccines landscape is being reshaped by the normalization of international travel after pandemic-era disruptions, stronger border health surveillance, and greater attention to outbreaks that can spread across regions through mobility networks. Guidance from organizations such as the CDC, WHO, ECDC, PAHO, and national health ministries increasingly influences patient decision-making, especially for destinations with International Certificate of Vaccination or Prophylaxis requirements for yellow fever or elevated risk of mosquito-borne, foodborne, waterborne, and respiratory infections.

Travel clinics are also adapting to consumer expectations for faster access and clearer documentation. Online appointment scheduling, pharmacist-led vaccination in many jurisdictions, electronic vaccine records, and bundled pre-travel consultations are shifting the competitive basis from product availability alone to service quality, trusted clinical interpretation, and timely compliance with destination-specific health requirements.

Cumulative Impact of Artificial Intelligence on Travel Vaccines

Artificial intelligence is becoming a practical enabler for travel medicine rather than a replacement for clinical judgment. AI-supported tools can synthesize itinerary details, duration of stay, seasonality, accommodation type, planned activities, patient age, pregnancy status, immune status, medical history, and prior immunization records to flag vaccine needs and timing constraints. This supports more consistent triage and reduces missed recommendations for multi-dose schedules and last-minute travelers.

AI also improves operational performance by forecasting clinic demand around school breaks, religious pilgrimage seasons, business travel cycles, study-abroad periods, and outbreak-related surges. When integrated with cold-chain inventory systems, electronic health records, and pharmacovigilance workflows, AI can reduce waste, improve appointment capacity, support recall systems, and accelerate detection of safety signals while keeping licensed clinicians responsible for final recommendations and informed consent.

Key Regional Insights for Travel Vaccines

Asia-Pacific represents one of the most dynamic regions for travel vaccines because it combines major outbound travel markets, high intraregional mobility, tropical disease exposure, and growing middle-class demand for preventive care. The region also includes destinations where travelers may require counseling on Japanese encephalitis, typhoid, hepatitis A, rabies, cholera risk in specific settings, and routine immunization updates. North America remains a high-value travel health environment due to mature travel medicine infrastructure, CDC and national guidance adoption, strong pharmacy vaccination channels, and large volumes of leisure, education, business, and visiting-friends-and-relatives travel.

Latin America presents mixed demand drivers, including tourism, business travel, ecotourism, and yellow fever risk in selected areas, with PAHO and national health authority updates playing an important role in traveler counseling. Europe benefits from established public health agencies, high outbound travel frequency, structured vaccination guidance across national systems, and strong demand for documentation-ready pre-travel services. The Middle East is shaped by pilgrimage travel, expatriate labor flows, and aviation hub connectivity, with meningococcal vaccination for Hajj and Umrah remaining a highly visible requirement under Saudi health regulations. Africa continues to require close attention because of yellow fever-endemic areas, meningitis belt considerations, malaria prevention needs, and uneven vaccine access, making reliable travel health counseling essential for inbound and outbound travelers.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN demand is supported by dense regional travel, tourism recovery, labor mobility, and exposure to diseases such as Japanese encephalitis, typhoid, hepatitis A, and rabies in specific settings, making itinerary-specific counseling highly relevant. GCC countries are strategically important because of pilgrimage management, international workforce mobility, aviation hub connectivity, and investment in digitally enabled healthcare systems that can support vaccine documentation and traveler compliance. The European Union offers a sophisticated regulatory and public health environment where travel advice is strongly influenced by national institutes, ECDC surveillance, cross-border health coordination, and high outbound mobility.

BRICS countries are important both as outbound travel sources and as vaccine manufacturing, procurement, and immunization-policy stakeholders, particularly across China, India, Brazil, Russia, and South Africa. G7 markets drive premium travel medicine demand through high international travel volumes, strong public health literacy, mature clinical delivery networks, and established private-pay or reimbursement pathways in selected systems. NATO countries add an occupational and defense-health dimension, where deployment readiness, rapid documentation, standardized immunization records, and protection against region-specific pathogens are operational priorities for military, contractor, and humanitarian mobility.

Key Country Insights for Priority Travel Vaccine Markets

In the United States, travel vaccine demand is supported by CDC Travelers' Health recommendations, large outbound travel volumes, study-abroad programs, employer travel, and expanding pharmacy access. Canada shows similar demand through federal and provincial public health guidance, strong travel clinic networks, and high outbound leisure travel, while Mexico and Brazil are influenced by domestic tourism, business travel, regional mobility, and yellow fever or other tropical disease considerations in selected areas. The United Kingdom, Germany, France, Italy, and Spain remain major European travel vaccine markets because of high outbound tourism, business mobility, mature healthcare systems, and established public health guidance that supports pre-travel consultation.

Russia presents a distinct travel health environment influenced by regional mobility, public-sector healthcare structures, and outbound travel to Asia, the Middle East, and Europe. China and India are major growth-oriented travel health markets because of large populations, rising outbound travel, expanding private healthcare access, and increasing awareness of preventive vaccination for education, work, pilgrimage, and tourism. Japan, Australia, and South Korea combine high travel intensity with strong public health literacy, digital health adoption, and structured vaccine documentation practices, making them attractive markets for digital pre-travel counseling, reminder systems, and evidence-based travel immunization services.

Actionable Recommendations for Travel Health Leaders

Industry leaders should prioritize integrated travel health pathways that begin at trip planning and continue through post-travel follow-up. Clinics should standardize itinerary-based risk assessment, maintain current guidance from recognized authorities, and use electronic reminders to improve multi-dose series completion for vaccines such as hepatitis A/B, rabies pre-exposure prophylaxis, and Japanese encephalitis where appropriate.

Providers should also strengthen cold-chain governance, reduce stockouts through demand forecasting, and partner with employers, universities, travel agencies, airlines, insurers, and community pharmacies to reach travelers earlier. Clear patient education is essential: recommendations must explain destination risk, vaccine timing, certificate requirements, contraindications, coadministration considerations, and the continued need for non-vaccine prevention such as mosquito avoidance, food and water precautions, traveler's diarrhea preparation, and malaria chemoprophylaxis when indicated.

Research Methodology for Travel Vaccines Analysis

This executive summary is developed using a triangulated research approach that integrates public health guidance, regulatory sources, surveillance updates, travel trend indicators, and industry practice analysis. Core reference categories include WHO disease and immunization guidance, CDC Travelers' Health recommendations, ECDC and PAHO surveillance resources, national immunization policies, vaccine labeling information, International Health Regulations requirements, and aviation or tourism mobility indicators from recognized institutions.

The methodology emphasizes verified evidence, cross-source validation, and practical market interpretation. Disease risk, vaccine eligibility, regional demand drivers, access dynamics, and service delivery trends are assessed through a combination of epidemiological relevance, traveler behavior, healthcare delivery capacity, policy requirements, and documented clinical guidance. Insights are written for decision-making and should be paired with jurisdiction-specific clinical guidance before implementation.

Conclusion: Strategic Outlook for Travel Vaccines

Travel vaccines are positioned for sustained strategic importance as global mobility, outbreak awareness, and preventive health expectations continue to rise. Demand will favor organizations that combine trusted clinical guidance with convenient access, digital documentation, reliable inventory, and personalized itinerary-based recommendations aligned with recognized public health guidance.

For providers, success depends on moving beyond transactional vaccination toward comprehensive travel medicine. Organizations that invest in AI-enabled triage, evidence-based counseling, cold-chain resilience, safety monitoring, and partnerships across travel, education, corporate health, pharmacy, and public health ecosystems will be best positioned to meet traveler needs while improving protection against vaccine-preventable diseases.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Travel Vaccines Market, by Vaccine Type

• 7.1. Routine Vaccines
  • 7.1.1. Hepatitis A
  • 7.1.2. Hepatitis B
  • 7.1.3. Polio
  • 7.1.4. Measles, Mumps, Rubella (MMR)
• 7.2. Travel-Specific Vaccines
  • 7.2.1. Yellow Fever
  • 7.2.2. Typhoid
  • 7.2.3. Cholera
  • 7.2.4. Japanese Encephalitis
  • 7.2.5. Rabies

8. Travel Vaccines Market, by Form

• 8.1. Injectable
• 8.2. Oral

9. Travel Vaccines Market, by Age Group

• 9.1. Adult
• 9.2. Pediatric
• 9.3. Geriatric

10. Travel Vaccines Market, by End User

• 10.1. Hospitals & Clinics
• 10.2. Online Pharmacies
• 10.3. Pharmacies
• 10.4. Travel Clinics

11. Travel Vaccines Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Travel Vaccines Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Travel Vaccines Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. AstraZeneca PLC
• 15.3. Bavarian Nordic A/S
• 15.4. Bharat Biotech International Limited
• 15.5. Bio-Manguinhos
• 15.6. Bio-Med (P) Limited
• 15.7. Biological E Limited
• 15.8. Cadila Pharmaceuticals Limited
• 15.9. CSL Limited
• 15.10. Dano Vaccines & Biologicals Private Limited
• 15.11. Dynavax Technologies Corporation
• 15.12. Emergent BioSolutions Inc.
• 15.13. GlaxoSmithKline plc
• 15.14. Incepta Pharmaceuticals Ltd.
• 15.15. Indian Immunologicals Ltd.
• 15.16. Johnson & Johnson Services, Inc
• 15.17. Merck & Co., Inc.
• 15.18. Novartis AG
• 15.19. Perusahaan Umum (Persero) Bio Farma
• 15.20. Pfizer Inc.
• 15.21. Sanofi S.A.
• 15.22. Serum Institute of India Pvt. Ltd.
• 15.23. Shenzhen Kangtai Biological Products Co., Ltd.
• 15.24. Takeda Pharmaceutical Company Limited
• 15.25. Valneva SE
• 15.26. Walvax Biotechnology Co., Ltd.